Acadia’s shot at beating a ‘fickle’ major depression challenge misses the mark in a failed PhIII
Acadia’s hit-and-miss record with Nuplazid (pimavanserin) has just missed a big Phase III mark by a wide margin.
The biotech $ACAD reports that its revised late-stage effort on their combined CLARITY-2 and CLARITY-3 trials for major depression — which had each enrolled about 50% of the patients initially anticipated — failed the primary endpoint with a p value of 0.296.
The drug did clear the bar on a key secondary endpoint, with a marginally positive score on Clinical Global Impression – Severity (CGI-S). And it follows a successful Phase II in the first study, where the drug significantly reduced HAMD-17.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
